Who are Fixed Combination Bimatoprost and Timolol's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fixed-combination-bimatoprost-and-timolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fixed Combination Bimatoprost and Timolol — Competitive Intelligence Brief

Fixed Combination Bimatoprost and Timolol (Fixed Combination Bimatoprost and Timolol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog and beta-adrenergic receptor blocker. Area: Ophthalmology.

phase 2 Prostaglandin analog and beta-adrenergic receptor blocker Prostaglandin receptors and beta-adrenergic receptors Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Fixed Combination Bimatoprost and Timolol (Fixed Combination Bimatoprost and Timolol) — Allergan. Bimatoprost is a prostaglandin analog that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fixed Combination Bimatoprost and Timolol TARGET	Fixed Combination Bimatoprost and Timolol	Allergan	phase 2	Prostaglandin analog and beta-adrenergic receptor blocker	Prostaglandin receptors and beta-adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog and beta-adrenergic receptor blocker class)

Allergan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fixed Combination Bimatoprost and Timolol — Competitive Intelligence Brief. https://druglandscape.com/ci/fixed-combination-bimatoprost-and-timolol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab